ECSP23093588A - Composiciones de suministro de terapia génica y métodos para tratar perdida auditiva - Google Patents

Composiciones de suministro de terapia génica y métodos para tratar perdida auditiva

Info

Publication number
ECSP23093588A
ECSP23093588A ECSENADI202393588A ECDI202393588A ECSP23093588A EC SP23093588 A ECSP23093588 A EC SP23093588A EC SENADI202393588 A ECSENADI202393588 A EC SENADI202393588A EC DI202393588 A ECDI202393588 A EC DI202393588A EC SP23093588 A ECSP23093588 A EC SP23093588A
Authority
EC
Ecuador
Prior art keywords
methods
hearing loss
gene therapy
therapy delivery
delivery compositions
Prior art date
Application number
ECSENADI202393588A
Other languages
English (en)
Inventor
Danielle R Lenz
Hao Chiang
Emmanuel John Simons
Robert Ng
Original Assignee
Akouos Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Akouos Inc filed Critical Akouos Inc
Publication of ECSP23093588A publication Critical patent/ECSP23093588A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/36—Skin; Hair; Nails; Sebaceous glands; Cerumen; Epidermis; Epithelial cells; Keratinocytes; Langerhans cells; Ectodermal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
    • A61K48/0025—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid
    • A61K48/0041—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid the non-active part being polymeric
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A61K48/0058—Nucleic acids adapted for tissue specific expression, e.g. having tissue specific promoters as part of a contruct
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0075—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the delivery route, e.g. oral, subcutaneous
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Plant Pathology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Developmental Biology & Embryology (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Infusion, Injection, And Reservoir Apparatuses (AREA)

Abstract

La presente divulgación proporciona constructos que comprenden una secuencia codificante enlazada operativamente a un promotor, en donde la secuencia codificante codifica un polipéptido (por ejemplo, un polipéptido terapéutico). Constructos de ejemplo incluyen constructos de AAV. También se proporcionan métodos para usar los constructos divulgado para el tratamiento de pérdida auditiva y/o sordera.
ECSENADI202393588A 2021-05-13 2023-12-13 Composiciones de suministro de terapia génica y métodos para tratar perdida auditiva ECSP23093588A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163188450P 2021-05-13 2021-05-13
US202163251025P 2021-09-30 2021-09-30
US202163277549P 2021-11-09 2021-11-09

Publications (1)

Publication Number Publication Date
ECSP23093588A true ECSP23093588A (es) 2024-01-31

Family

ID=84028799

Family Applications (1)

Application Number Title Priority Date Filing Date
ECSENADI202393588A ECSP23093588A (es) 2021-05-13 2023-12-13 Composiciones de suministro de terapia génica y métodos para tratar perdida auditiva

Country Status (13)

Country Link
EP (1) EP4337226A1 (es)
JP (1) JP2024521052A (es)
KR (1) KR20240021799A (es)
AU (1) AU2022271727A1 (es)
CA (1) CA3218877A1 (es)
CO (1) CO2023017148A2 (es)
CR (1) CR20230577A (es)
DO (1) DOP2023000248A (es)
EC (1) ECSP23093588A (es)
IL (1) IL308396A (es)
MX (1) MX2023013394A (es)
PE (1) PE20240240A1 (es)
WO (1) WO2022240778A1 (es)

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070161031A1 (en) * 2005-12-16 2007-07-12 The Board Of Trustees Of The Leland Stanford Junior University Functional arrays for high throughput characterization of gene expression regulatory elements
WO2019200016A1 (en) * 2018-04-10 2019-10-17 President And Fellows Of Harvard College Aav vectors encoding clarin-1 or gjb2 and uses thereof

Also Published As

Publication number Publication date
PE20240240A1 (es) 2024-02-16
AU2022271727A9 (en) 2024-01-04
CA3218877A1 (en) 2022-11-17
AU2022271727A1 (en) 2023-12-14
WO2022240778A1 (en) 2022-11-17
EP4337226A1 (en) 2024-03-20
DOP2023000248A (es) 2024-01-31
CR20230577A (es) 2024-03-11
KR20240021799A (ko) 2024-02-19
JP2024521052A (ja) 2024-05-28
IL308396A (en) 2024-01-01
MX2023013394A (es) 2023-12-14
CO2023017148A2 (es) 2024-01-15

Similar Documents

Publication Publication Date Title
CL2022003147A1 (es) Composiciones y métodos para tratar pérdida auditiva asociada con gjb2
CL2021000112A1 (es) Composiciones y métodos para aumentar o mejorar la transducción de vectores de terapia genética y para eliminar o reducir las inmunoglobulinas
BR112022007158A2 (pt) Agentes imunomodulatórios de il-2 em combinação com inibidores do ponto de verificação imunológico
CO2021007916A2 (es) Ácido ribonucleico (arn) que codifica para una proteína
CO2022012917A2 (es) Vectores de genoterapia para tratar enfermedades cardíacas
CL2020003190A1 (es) Terapia génica cardíaca con aav para cardiomiopatía.
BR112022008214A2 (pt) Composições e métodos para tratar perda auditiva neurossensorial usando sistemas de vetor duplo de otoferlina
ECSP23093588A (es) Composiciones de suministro de terapia génica y métodos para tratar perdida auditiva
CL2022003153A1 (es) Composiciones y métodos para tratar la pérdida auditiva asociada a slc26a4
ECSP21087921A (es) Materiales y métodos para modular la inmunidad mediada por células t
CO2023010473A2 (es) Composiciones y métodos de terapia celular para modular la señalización del tgf-b
DOP2023000202A (es) Terapia de combinación que implica anticuerpos contra claudina 18.2 para el tratamiento del cáncer.
CL2020001494A1 (es) Uso de una proteína no estructural de prv para proteger contra la inflamación del músculo esquelético y cardíaco.
ECSP23057004A (es) Composiciones y métodos para tratar la pérdida de audición y/o la pérdida de visión asociada a clrn1
ECSP22049399A (es) C?lula vector adyuvante artificial con contenido de ny?eso?1 para usar en el tratamiento del c?ncer
CO2022006772A2 (es) Composiciones y métodos para el tratamiento de los trastornos de almacenamiento de glucógeno
WO2022067340A3 (en) Methods and compositions for the treatment of neurodegenerative diseases
CO2021005872A2 (es) Composiciones y métodos para la estimulación ovárica controlada
CR7622A (es) Secuencias del control del gen de corina humano
BR112022020846A2 (pt) Agentes imunoestimuladores em combinação com inibidores de angiogênese
AR120198A1 (es) Construcciones de variantes de igf2
AR127675A1 (es) Terapia génica para el tratamiento de la ht1
AR121245A1 (es) Composiciones útiles para tratar gangliosidosis gm1
ECSP23034907A (es) Ácido nucleico que codifica una entidad anti–vegf y un regulador del complemento negativo y sus usos para el tratamiento de la degeneración macular relacionada con la edad
MX2022012983A (es) Agentes inmunoestimulantes en combinación con inhibidores de la angiogénesis.